1239 related articles for article (PubMed ID: 26042883)
1. Indications for pacemakers, implantable cardioverter-defibrillator and cardiac resynchronization devices.
Samii SM
Med Clin North Am; 2015 Jul; 99(4):795-804. PubMed ID: 26042883
[TBL] [Abstract][Full Text] [Related]
2. Roles and indications for use of implantable defibrillator and resynchronization therapy in the prevention of sudden cardiac death in heart failure.
Biton Y; Baman JR; Polonsky B
Heart Fail Rev; 2016 Jul; 21(4):433-46. PubMed ID: 26910804
[TBL] [Abstract][Full Text] [Related]
3. Clinical management of arrhythmias in elderly patients: results of the European Heart Rhythm Association survey.
Chen J; Hocini M; Larsen TB; Proclemer A; Sciaraffia E; Blomström-Lundqvist C;
Europace; 2015 Feb; 17(2):314-7. PubMed ID: 25634939
[TBL] [Abstract][Full Text] [Related]
4. Saving lives and reducing inappropriate device therapy: the MADIT family of implantable cardioverter-defibrillator and cardiac resynchronization therapy trials.
Moss AJ
Cardiol J; 2013; 20(3):217-9. PubMed ID: 23788293
[No Abstract] [Full Text] [Related]
5. Cardiac Implantable Electronic Device Therapy: Permanent Pacemakers, Implantable Cardioverter Defibrillators, and Cardiac Resynchronization Devices.
Steffen MM; Osborn JS; Cutler MJ
Med Clin North Am; 2019 Sep; 103(5):931-943. PubMed ID: 31378335
[TBL] [Abstract][Full Text] [Related]
6. Implantable defibrillators and cardiac resynchronization therapy in heart transplant recipients: results of a national survey.
McDowell DL; Hauptman PJ
J Heart Lung Transplant; 2009 Aug; 28(8):847-50. PubMed ID: 19632584
[TBL] [Abstract][Full Text] [Related]
7. Newer Indications for ICD and CRT.
Merriam JA; Rajendra AB; Gold MR
Cardiol Clin; 2014 May; 32(2):181-90. PubMed ID: 24793795
[TBL] [Abstract][Full Text] [Related]
8. Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon.
Boriani G; Braunschweig F; Deharo JC; Leyva F; Lubinski A; Lazzaro C
Europace; 2013 Oct; 15(10):1453-62. PubMed ID: 23696624
[TBL] [Abstract][Full Text] [Related]
9. Eligibility of Pacemaker Patients for Subcutaneous Implantable Cardioverter Defibrillators.
Ip JE; Wu MS; Kennel PJ; Thomas G; Liu CF; Cheung JW; Markowitz SM; Lerman BB
J Cardiovasc Electrophysiol; 2017 May; 28(5):544-548. PubMed ID: 28185354
[TBL] [Abstract][Full Text] [Related]
10. Cardiac Arrhythmias in Adults with Congenital Heart Disease: Pacemakers, Implantable Cardiac Defibrillators, and Cardiac Resynchronization Therapy Devices.
Cecchin F; Halpern DG
Card Electrophysiol Clin; 2017 Jun; 9(2):319-328. PubMed ID: 28457245
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular implantable electronic devices in athletes.
Do R; Patton KK
Cardiovasc Ther; 2010 Oct; 28(5):327-36. PubMed ID: 20553287
[TBL] [Abstract][Full Text] [Related]
12. Replacement of implantable cardioverter defibrillators and cardiac resynchronization therapy devices: results of the European Heart Rhythm Association survey.
Tilz R; Boveda S; Deharo JC; Dobreanu D; Haugaa KH; Dagres N
Europace; 2016 Jun; 18(6):945-9. PubMed ID: 27297231
[TBL] [Abstract][Full Text] [Related]
13. Cardiac resynchronization therapy: what? Who? When? How?
Cuculich PS; Joseph S
Am J Med; 2011 Sep; 124(9):813-5. PubMed ID: 21854888
[TBL] [Abstract][Full Text] [Related]
14. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
[TBL] [Abstract][Full Text] [Related]
15. Sex differences in implantable cardioverter-defibrillator implantation indications and outcomes: lessons from the Nationwide Israeli-ICD Registry.
Amit G; Suleiman M; Konstantino Y; Luria D; Kazatsker M; Chetboun I; Haim M; Gavrielov-Yusim N; Goldenberg I; Glikson M;
Europace; 2014 Aug; 16(8):1175-80. PubMed ID: 24554524
[TBL] [Abstract][Full Text] [Related]
16. When an implantable defibrillator fails. Here are the options when the leads on your device stop working.
Harv Heart Lett; 2012 Aug; 22(12):3. PubMed ID: 23025020
[No Abstract] [Full Text] [Related]
17. Approach to reduction of ventricular arrhythmias and implantable cardioverter-defibrillator therapies in patients with heart failure.
Sengupta J; Abdelhadi R
Curr Opin Cardiol; 2013 May; 28(3):337-43. PubMed ID: 23549236
[TBL] [Abstract][Full Text] [Related]
18. The automatic implantable cardioverter-defibrillator: technology for preventing sudden cardiac death.
Thakor NV; Natarajan A
Med Des Mater; 1991 Mar; 1(3):16-24. PubMed ID: 10147992
[TBL] [Abstract][Full Text] [Related]
19. [Variables of arrhythmia risk in relation to pacemaker and implantable defibrillator].
Solano A; Oddone D; Croci F; Donateo P; Puggioni E; Brignole M
Ital Heart J Suppl; 2001 Dec; 2(12):1303-7. PubMed ID: 11838352
[TBL] [Abstract][Full Text] [Related]
20. [Leadless pacemakers and subcutaneously implantable cardioverter defibrillators].
Stellbrink C; Hansky B; Meyer Zu Vilsendorf D
Internist (Berl); 2018 Oct; 59(10):999-1010. PubMed ID: 30105398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
